The interaction of the host immunity with tumor cells has been identified as a hallmark of cancer based on the rapid development of immune-checkpoint blocking immunotherapy [4], predominately centered on programmed cell death protein 1 (PD1) [5]. The gene discussed is PDCD1; the disease is neoplasm.